Sagimet Biosciences Inc.
SGMT
$10.55
$1.2713.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.19% | 5.89% | 11.40% | 12.26% | 8.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.32% | -25.65% | 4.47% | 40.66% | 74.75% |
| Operating Income | 21.32% | 25.65% | -4.47% | -40.66% | -84.39% |
| Income Before Tax | 20.72% | 23.82% | -12.01% | -53.72% | -103.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.72% | 23.82% | -12.01% | -53.72% | -103.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.72% | 23.82% | -12.01% | -53.72% | -103.01% |
| EBIT | 21.32% | 25.65% | -4.47% | -40.66% | -84.39% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 30.54% | 24.51% | -9.60% | -39.13% | -56.44% |
| Normalized Basic EPS | 30.54% | 24.51% | -9.58% | -39.10% | -56.43% |
| EPS Diluted | 30.54% | 24.51% | -9.60% | -39.13% | -56.44% |
| Normalized Diluted EPS | 30.54% | 24.51% | -9.58% | -39.10% | -56.43% |
| Average Basic Shares Outstanding | 17.04% | 1.01% | 3.26% | 10.73% | 25.47% |
| Average Diluted Shares Outstanding | 17.04% | 1.01% | 3.26% | 10.73% | 25.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |